Biotech · Private company
EyeBiotech Ltd.
Track this companyFree. Adds EyeBiotech Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials75 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- AfliberceptPhase 3 · Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- RanibizumabPhase 3 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- RemigromigPhase 3 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- TiespectusPhase 3 · Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Aflibercept 2.0 mgPhase 2 · Neovascular Age-Related Macular Degeneration (NVAMD)ClinicalTrials.gov · fetched Nov 12, 2026
- EYE201Phase 2 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- RemigromigPhase 2 · Neovascular Age-Related Macular Degeneration (NVAMD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)PHASE2_PHASE3 · RECRUITING · started Apr 15, 2026ClinicalTrials.gov NCT07496567 · fetched Nov 12, 2026
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)PHASE2_PHASE3 · RECRUITING · started Mar 27, 2026ClinicalTrials.gov NCT07440225 · fetched Nov 12, 2026
- A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVOPHASE2 · RECRUITING · started Sep 12, 2025ClinicalTrials.gov NCT07205887 · fetched Nov 12, 2026
- A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Apr 16, 2025ClinicalTrials.gov NCT06957080 · fetched Nov 12, 2026
- A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular DegenerationPHASE1_PHASE2 · COMPLETED · started Nov 12, 2024ClinicalTrials.gov NCT06664502 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Aug 7, 2024ClinicalTrials.gov NCT06571045 · fetched Nov 12, 2026
- A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)PHASE1_PHASE2 · COMPLETED · started Jun 12, 2023ClinicalTrials.gov NCT05919693 · fetched Nov 12, 2026